Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.

• Authors: Joyce E Rundhaug
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 9 Issue 2 Pg. 551-4 (Feb 2003) ISSN: 1078-0432 [Print] United States
• PMID: 12576417 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Imidazoles
• Organic Chemicals
• N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide
• Matrix Metalloproteinases

Topics

• Antineoplastic Agents (therapeutic use)
• Humans
• Imidazoles
• Matrix Metalloproteinases (metabolism)
• Neoplasms (blood supply, drug therapy)
• Neovascularization, Pathologic
• Organic Chemicals